The biological underpinnings of therapeutic resistance in pancreatic cancer

76Citations
Citations of this article
79Readers
Mendeley users who have this article in their library.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in the United States and has only recently achieved a 5-yr survival rate of 10%. This dismal prognosis reflects the remarkable capacity of PDAC to effectively adapt to and resist therapeutic intervention. In this review, we discuss recent advances in our understanding of the biological underpinnings of PDAC and their implications as targetable vulnerabilities in this highly lethal disease.

Cite

CITATION STYLE

APA

Beatty, G. L., Werba, G., Lyssiotis, C. A., & Simeone, D. M. (2021, July 1). The biological underpinnings of therapeutic resistance in pancreatic cancer. Genes and Development. Cold Spring Harbor Laboratory Press. https://doi.org/10.1101/GAD.348523.121

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free